Publications by authors named "Christoph Helwig"

Claim this Profile
L
Letter to the editor in response to 'A real-world study of ART in France (REOLA) comparing a biosimilar rFSH against the originator according to rFSH starting dose' by P. Barrière, S. Hamamah, E. Arbo, C. Avril, B. Salle, J.-L. Pouly, et al. (J Gynecol Obstet Hum Reprod. 2023;52(1):102510).
Susana Montenegro, Christoph Helwig, Juan-Enrique Schwarze, Claire Castello-Bridoux, Sebastien Marque

J Gynecol Obstet Hum Reprod· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Biosimilar recombinant follitropin alfa preparations versus the reference product (Gonal-F®) in couples undergoing assisted reproductive technology treatment: a systematic review and meta-analysis.
Christos A Venetis, Christoph Helwig, Ben W Mol, Su Jen Chua, Salvatore Longobardi

Reprod Biol Endocrinol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.
Fabrice Barlesi, Nicolas Isambert, Enriqueta Felip, Byoung Chul Cho, Dae Ho Lee, Christoph Helwig

Oncologist· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk assessment of drug-drug interaction potential for bintrafusp alfa with cytochrome P4503A4 substrates: A totality of evidence approach.
Yulia Vugmeyster, George Locke, Christoph Helwig, P Alexander Rolfe, Jennifer Q Dong

Clin Transl Sci· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Chia-Chi Lin, Toshihiko Doi, Kei Muro, Ming-Mo Hou, Taito Esaki, Christoph Helwig

Target Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort.
Benjamin Tan, Adnan Khattak, Enriqueta Felip, Karen Kelly, Patricia Rich, Christoph Helwig

Target Oncol· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma.
Mustafa Khasraw, Michael Weller, David Lorente, Kathryn Kolibaba, Chee Khoon Lee, Christoph Helwig

Neurooncol Adv· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Toshihiko Doi, Yutaka Fujiwara, Takafumi Koyama, Masafumi Ikeda, Christoph Helwig

Oncologist· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay.
Hans Juergen Grote, Zheng Feng, Michael Schlichting, Christoph Helwig, Mary Ruisi

J Thorac Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Second-Line Treatment of Patients With NSCLC: Results From an Expansion Cohort of a Phase 1 Trial.
Luis Paz-Ares, Tae Min Kim, David Vicente, Enriqueta Felip, Dae Ho Lee, Christoph Helwig

J Thorac Oncol· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Yoon-Koo Kang, Yung-Jue Bang, Shunsuke Kondo, Hyun Cheol Chung, Kei Muro, Christoph Helwig

Clin Cancer Res· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort.
Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolas Isambert, Christoph Helwig

J Immunother Cancer· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with pretreated biliary tract cancer.
Changhoon Yoo, Do-Youn Oh, Hye Jin Choi, Masatoshi Kudo, Makoto Ueno, Christoph Helwig

J Immunother Cancer· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors.
Julius Strauss, Christopher R Heery, Jeffrey Schlom, Ravi A Madan, Liang Cao, Christoph Helwig

Clin Cancer Res· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of real-world treatment outcomes in patients with distant metastatic Merkel cell carcinoma following second-line chemotherapy in Europe.
Jürgen C Becker, Eva Lorenz, Selma Ugurel, Thomas K Eigentler, Felix Kiecker, Christoph Helwig

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA.
C Lance Cowey, Lisa Mahnke, Janet Espirito, Christoph Helwig, Dina Oksen

Future Oncol· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I/II study of tecemotide as immunotherapy in Japanese patients with unresectable stage III non-small cell lung cancer.
Nobuyuki Katakami, Toyoaki Hida, Hiroshi Nokihara, Fumio Imamura, Hiroshi Sakai, Christoph Helwig

Lung Cancer· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.
Charles Butts, Mark A Socinski, Paul L Mitchell, Nick Thatcher, Libor Havel, Christoph Helwig

Lancet Oncol· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis